Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		_ MEMBER'S FIRST I	NAME:	
	iew (e.g., chart notes or	lab data, to support th	<ul> <li>Attach any additional documentation e authorization request). Information</li> </ul>	
			☐ URGENT	
MEMBER INFORMATION	N			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTI	Н:	
STREET ADDRESS:		-		
CITY:		STATE:	ZIP CODE:	
PATIENT INSURANCE II	NUMBER:	l		
MALE FEMALE	HEIGHT (IN/CM):	_ WEIGHT (LB/KG):	ALLERGIES:	
IF YOU ARE NOT THE PADISCLOSURE AUTHORIZE FOLLOWING LINK: PRIM	ATION FORM WITH THE THERAPEUTICS.COM	IIS REQUEST WHICH M/NOPP	I CAN BE FOUND AT THE	
<b>AUTHORIZED REPRESE</b>				
PRESCRIBER INFORMA	TION			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIAL	TY:	EMAIL ADDRES	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE:	ZIP CODE:	
REQUESTER (if different than prescriber):		OFFICE CONTA	OFFICE CONTACT PERSON:	
		I		
MEDICATION OR MEDIC	CAL DISPENSING INFO	RMATION		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	QUANTITY:	
☐ NEW THERAPY		RENEWAL: DATE T		
Continued on post page	Y (SPECIFIC DATES):			
Continued on next page				

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 7.1.2025 CAT009



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	NAME:			
1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?					
YES (if yes, complete below) NO					
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
Active ankylosing spondylitis Moderate to severely active psoriation Moderate to severely active rheuma Polyarticular juvenile idiopathic arthr Ulcerative colitis					
Other diagnosis:Code(s):	ICD-10				
<b>3. REQUIRED CLINICAL INFORMATION:</b> PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.					
Is patient going to be using drug in combination with a clinical trial?   Yes No Will the patient be taking Simponi concurrently with another biologic or immunomodulatory agent, such as Kineret, Remicade, Rituxan, Orencia, Cimzia, Enbrel, Otezla, Actemra or Xeljanz, etc.,?  Yes No  Select if Simponi is prescribed by the following specialists:  Dermatologist  Rheumatologist  Gastroenterologist					
Has the patient tried and had an inadequate response to a three month trial of the <u>biosimilar</u> for Humira- <u>adalimumab-aacf</u> ?    Yes   No Please submit documentation.					
Does patient have a absolute contraindication to the biosimilar for Humira- adalimumab-aacf?   No Please submit documentation.					
Has the patient tried and had an inadequate response to a trial of the <u>biosimilar</u> for Actemra, Tyenne(tocilizumab-aazg)? □ Yes □ No Please submit documentation.					
Does patient have a absolute contraindication to the biosimilar for Actemra, Tyenne(tocilizumabazg)?   No Please submit documentation.					
Has the patient tried and had an inadequate response to a 4- month trial of the <u>biosimilar</u> for Stelara- Otulfi(ustekinumb-aauz)?   Yes  No Please submit documentation.					



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
Does patient have a absolute contraindication ☐ Yes ☐ No Please submit documentation.	n to the biosimilar for Stelara- <u>Otulfi(ustekinumb-aauz)?</u>
For <u>active ankylosing spondylitis</u> , also answer Has the patient tried and failed at least two (2 NSAIDs?* □ Yes □ No *Must submit doc	) NSAIDS or does the patient have a contraindication to
Has the patient tried and failed methotrexate	? □ Yes □ No *Must submit documentation.
	ritis, also answer the following: ponse to oral disease-modifying anti-rheumatic agents ne, cyclosporine or leflunamide(Arava)?* □ Yes □ No
	MARD due to chronic liver disease such as chronic itis/NASH, or elevated liver enzymes?*   Yes   No
	de rationale (if applicable), explaining why the patient is o severely active rheumatoid arthritis, also answer the
	ponse to methotrexate or another oral non-biologic ARD) such as Imuran, Ridaura, sulfasalazine, Plaquenil
	MARD due to chronic liver disease such as chronic titis/NASH, or elevated liver enzymes?* □ Yes □ No
If "no" to the above question, please proviunable to take a DMARD:	de rationale (if applicable), explaining why the patient is
For ulcerative colitis, also answer the following	ng:
	of the following standard therapies:? □ Yes □ No*Must
<ul> <li>□ Corticosteroids such as prednisone or bud</li> <li>□ Mesalamine products; oral or rectal (Apriso</li> <li>□ Balsalazide (Colazal, Giazo)</li> <li>□ Olsalazine(Dipentum)</li> <li>□ Azathioprine</li> <li>□ 6-mercaptopurine</li> </ul>	esonide er (Entocort EC, Uceris) , Asacol, Canasa, Delzicol, Lialda, Pentasa. Rowasa)



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
Reauthorization: If this is a reauthorization request, answer the following questions: Will the patient be taking Simponi concurrently with another biologic or immunomodulatory agent, such as Kineret, Remicade, Rituxan, Orencia, Cimzia, Enbrel, Otezla, Actemra or Xeljanz?   No				
	e, and is remission of disease maintained with ase provide documentation.			
Select if Simponi is prescribed by the followin  Dermatologist Rheumatologist Gastroenterologist	g specialists:			
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
Please note: Not all drugs/diagnosis are covered required information is received.	on all plans. This request may be denied unless all			
<b>ATTESTATION:</b> I attest the information provided understand that the Health Plan, insurer, Medical	is true and accurate to the best of my knowledge. I Group or its designees may perform a routine audit and fy the accuracy of the information reported on this form.			
Prescriber Signature or Electronic I.D. Verifica	tion: Date:			
information that is legally privileged. If you are no disclosure, copying, distribution, or action taken in	companying this transmission contain confidential health the intended recipient, you are hereby notified that any reliance on the contents of these documents is strictly error, please notify the sender immediately (via return these documents.			

**FAX THIS FORM TO:** 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

